A US Food and Drug Administration advisory committee on 26 February narrowly endorsed a labeling expansion for Eli Lilly & Co.’s Cyramza (ramucirumab) in lung cancer but overwhelmingly said Steba Biotech’s prostate cancer therapy Tookad (padeliporfin di-potassium powder) is not ready for approval.
By a one-vote margin, the Oncologic Drugs Advisory Committee endorsed the benefit/risk profile for ramucirumab, in combination with Genentech...





